Kendall-Taylor P, Knox A J, Steel N R, Atkinson S
Lancet. 1984 Mar 24;1(8378):654-6. doi: 10.1016/s0140-6736(84)92171-8.
The hyperthyroidism in Graves' disease results from the action of thyroid-stimulating antibodies (TSAb). The thyroid gland in Graves' disease shows diffuse lymphocytic infiltration, and after removal of the gland antibody titres usually decline and patients go into remission. It is postulated that the lymphocytes in the thyroid may be an important site of TSAb production. 10 patients with Graves' disease and 8 patients with other thyroid disorders were studied. Blood was taken during operation, but before thyroid mobilisation, from the thyroid vein and simultaneously from a peripheral vein. In patients with Graves' disease the concentration of TSAb activity in the thyroid vein was much greater than that in the peripheral vein. TSAb was not detected in either peripheral vein or thyroid vein samples in the other patients. The increase in TSAb concentration in the thyroid vein indicates production of antibodies by lymphocytes within the thyroid and could explain why removal of the thyroid results in disappearance of TSAb from the circulation.
格雷夫斯病中的甲状腺功能亢进是由促甲状腺抗体(TSAb)的作用引起的。格雷夫斯病患者的甲状腺呈现弥漫性淋巴细胞浸润,切除甲状腺后抗体滴度通常会下降,患者进入缓解期。据推测,甲状腺中的淋巴细胞可能是TSAb产生的重要部位。对10例格雷夫斯病患者和8例其他甲状腺疾病患者进行了研究。在手术过程中,但在甲状腺游离之前,从甲状腺静脉和同时从外周静脉采集血液。在格雷夫斯病患者中,甲状腺静脉中TSAb活性的浓度远高于外周静脉。在其他患者的外周静脉或甲状腺静脉样本中均未检测到TSAb。甲状腺静脉中TSAb浓度的增加表明甲状腺内的淋巴细胞产生了抗体,这可以解释为什么切除甲状腺会导致循环中的TSAb消失。